Rosa G. Liberman

Pfizer (United States)

Papers

1

Total Citations

61

H-Index

1

About

Rosa G. Liberman is a leading figure in the application of accelerator mass spectrometry (AMS) to biomedical research, with a career defined by pioneering advances in radiocarbon tracing. Her primary research areas include bioanalytical chemistry, isotope ratio mass spectrometry, and the development of novel interfaces for direct analysis of biological specimens. Liberman’s most notable contribution is the invention of a groundbreaking apparatus and method for the direct analysis of ¹⁴C in nonvolatile biological samples, such as plasma and urine, using AMS. This work, published in 2003 and cited over 60 times, revolutionized the field by eliminating complex sample preparation steps—allowing liquid samples to be deposited directly into a CuO powder bed for combustion and analysis. Her innovation dramatically improved throughput and sensitivity for tracing carbon-14 labeled compounds in metabolic studies, pharmacokinetics, and toxicology. By making AMS more accessible for biomedical applications, Liberman has enabled researchers to conduct highly precise, low-level radiocarbon measurements with unprecedented ease. Her work remains a cornerstone in the evolution of bioanalytical AMS, profoundly impacting how scientists study human metabolism and drug disposition.

Research Focus

Key Achievements

1
H-Index
1
Papers
61
Total Citations
61
Avg Citations/Paper
🏆 Most Cited Paper
An Interface for Direct Analysis of <sup>14</sup>C in Nonvolatile Samples by Accelerator Mass Spectrometry
61 citations · 2003
📈 Most Prolific Year: 2003 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Pfizer (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago